| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1046590272 |
| P356 | DOI | 10.1186/S13024-015-0043-6 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1186/s13024-015-0043-6 |
| P932 | PMC publication ID | 4580347 |
| P698 | PubMed publication ID | 26394760 |
| P5875 | ResearchGate publication ID | 282127597 |
| P50 | author | Eliezer Masliah | Q28324209 |
| Edward Rockenstein | Q28324218 | ||
| P2093 | author name string | Brian Spencer | |
| Elvira Valera | |||
| Anthony Adame | |||
| Margarita Trejo-Morales | |||
| P2860 | cites work | The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry | Q24291825 |
| The emergence of proteinase-activated receptor-2 as a novel target for the treatment of inflammation-related CNS disorders | Q24679499 | ||
| Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's disease | Q27437619 | ||
| Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies | Q28202726 | ||
| Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain | Q28249933 | ||
| Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy | Q28395248 | ||
| Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders | Q29614754 | ||
| Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Aβ uptake and degradation by astrocytes | Q30274560 | ||
| Widespread alterations of alpha-synuclein in multiple system atrophy | Q30444927 | ||
| Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. | Q40010392 | ||
| Cellular pathology of multiple system atrophy: a review | Q40724377 | ||
| Process outgrowth in oligodendrocytes is mediated by CNP, a novel microtubule assembly myelin protein | Q41888821 | ||
| Alpha-synuclein stimulation of astrocytes: Potential role for neuroinflammation and neuroprotection | Q42412086 | ||
| Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. | Q42486578 | ||
| Extracellular neurosin degrades α-synuclein in cultured cells. | Q43093480 | ||
| In vivo analysis of kallikrein-related peptidase 6 (KLK6) function in oligodendrocyte development and the expression of myelin proteins | Q44253648 | ||
| Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. | Q44979423 | ||
| Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. | Q45299732 | ||
| Transduction of liver cells by lentiviral vectors: analysis in living animals by fluorescence imaging. | Q45991699 | ||
| Production and purification of lentiviral vectors | Q46172190 | ||
| Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro. | Q46688857 | ||
| Characterization of proteinase-activated receptor 2 signalling and expression in rat hippocampal neurons and astrocytes | Q46907217 | ||
| Protease M/neurosin mRNA is expressed in mature oligodendrocytes | Q47920506 | ||
| Implications of protease M/neurosin in myelination during experimental demyelination and remyelination. | Q54588636 | ||
| Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease | Q64768820 | ||
| Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH | Q74459953 | ||
| Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy | Q30516504 | ||
| ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo | Q30650119 | ||
| Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases | Q33613123 | ||
| Cognitive impairments in multiple system atrophy of the cerebellar type | Q33636383 | ||
| Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy | Q33670282 | ||
| The mammalian low-density lipoprotein receptor family | Q33711776 | ||
| The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway | Q33757009 | ||
| A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis | Q33793059 | ||
| Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors | Q33958289 | ||
| Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). | Q34458365 | ||
| Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy | Q34544824 | ||
| Alpha-synuclein mRNA expression in oligodendrocytes in MSA. | Q34548507 | ||
| Accumulation of α-synuclein in dementia with Lewy bodies is associated with decline in the α-synuclein-degrading enzymes kallikrein-6 and calpain-1. | Q34739881 | ||
| Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer | Q34781039 | ||
| Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy | Q35544737 | ||
| Myelin degeneration in multiple system atrophy detected by unique antibodies | Q35753409 | ||
| Targeted delivery of proteins across the blood-brain barrier | Q35762072 | ||
| Alzheimer's β-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of β-amyloid | Q36246858 | ||
| Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD. | Q36512589 | ||
| Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. | Q36722978 | ||
| Novel strategies for Alzheimer's disease treatment | Q37012066 | ||
| Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission | Q37117527 | ||
| Cell-to-cell transmission of non-prion protein aggregates. | Q37200740 | ||
| Transmission of multiple system atrophy prions to transgenic mice | Q37353012 | ||
| α-Synuclein in Parkinson disease and other neurodegenerative disorders | Q37845823 | ||
| The role of glia in α-synucleinopathies | Q38039880 | ||
| The function of α-synuclein | Q38139561 | ||
| Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases | Q38185934 | ||
| Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. | Q38485003 | ||
| Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo | Q38966914 | ||
| Resistance of naturally secreted α-synuclein to proteolysis | Q39005218 | ||
| The degree of astrocyte activation in multiple system atrophy is inversely proportional to the distance to α-synuclein inclusions | Q39130671 | ||
| Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy | Q39405702 | ||
| Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. | Q39980342 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageQuant | Q112270642 |
| P921 | main subject | Synuclein | Q24767155 |
| P304 | page(s) | 48 | |
| P577 | publication date | 2015-09-23 | |
| P1433 | published in | Molecular Neurodegeneration | Q15817329 |
| P1476 | title | A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy | |
| P478 | volume | 10 |
| Q38372272 | Atypical Parkinsonian syndromes: a general neurologist's perspective |
| Q97519963 | Involvement of Kallikrein-Related Peptidases in Nervous System Disorders |
| Q37716380 | KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species. |
| Q58699560 | Kallikrein-related peptidase 6 orchestrates astrocyte form and function through proteinase activated receptor-dependent mechanisms |
| Q47653685 | Mitochondrial function and autophagy: integrating proteotoxic, redox, and metabolic stress in Parkinson's disease |
| Q39220912 | Multiple System Atrophy - State of the Art. |
| Q26771536 | Neuroinflammation in Multiple System Atrophy: Response to and Cause of α-Synuclein Aggregation |
| Q36672116 | Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy |
| Q89208306 | Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders |
| Q36489317 | Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease |
| Q64777173 | Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease |
| Q38754587 | Targeting α-synuclein: Therapeutic options |
| Q38691406 | Therapeutic approaches in Parkinson's disease and related disorders |
Search more.